We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Dr
Alexander
Heazell
alexander.heazell@manchester.ac.uk
Dr
Alexander
Heazell
alexander.heazell@manchester.ac.uk
Maternal care related to the fetus and amniotic cavity and possible delivery problems
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
During pregnancy the placenta (or afterbirth) is responsible for delivering fetal growth by transferring nutrients and
oxygen from the mothers blood stream. The development of the placenta must occur within weeks and is dependent
on a maternal environment. Abnormalities in this rapid process are common, resulting in abnormal
placental tissue development, abnormal materno-placental interaction or both. When these abnormalities occur they
result in the linked pregnancy diseases miscarriage, pre-eclampsia (high blood pressure and maternal multisystem
disease), fetal growth restriction (failed fetal growth during pregnancy) and stillbirth. Significant progress has been
made in determining some of the causal factors of placental failure postnatally when the placenta is examined.
However, how to antenatally detect these different placental phenotypes, and determine how the placenta functions as pregnancy features change, and as treatments are given, remains a challenge. We have developed placental MRI techniques over the last 8 years that can determine placental dysfunction, and identify different phenotypes, by measuring placental oxygenation. Our data has shown progressive changes in MRI measures of placental oxygenation across pregnancy gestation and between normal and complicated pregnancies. At present, we are unable to judge if any of current treatments for pregnancy complications (such as blood pressure medication, or metformin) are having any effect on placental function or these MRI parameters. This new study will aim to address this by developing new MR techniques, and refining existing protocols to assess placental function as pregnancy features change, and new treatments of pregnancy complications are introduced. Placental MRI scans will be developed from our prior protocols which have had a high participant satisfaction and completion rate.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Observational type: Case-controlled study;
You can take part if:
You may not be able to take part if:
• known chromosomal or structural abnormality in the fetus • claustrophobia • pacemakers, metal implants or objects (e.g. aneurysm clips) • participant age < 18 years • multiple pregnancy • those who, for reasons of language or learning difficulty, are unable to give informed consent Non-pregnant healthy volunteer group - prior splenectomy
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Dr
Alexander
Heazell
alexander.heazell@manchester.ac.uk
Dr
Alexander
Heazell
alexander.heazell@manchester.ac.uk
The study is sponsored by University of Manchester and funded by TOMMY'S .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 40976
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
